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Schlee et al. (2009) made a through
investigation on short dsRNA (<30 base
pairs [bp]) and determined the optimal 50
tri-p RNA structure for RIG-I activation.
They chemically synthesized 50 tri-p
single-stranded RNA and annealed them
with different lengths of complementary
RNA strands for analysis. It was found
that the optimal structure was blunt
ended 50 tri-p dsRNA with >20 bp.
The genome of many negative-strand
viruses, including influenza A, Rabies,
and Measles viruses, contain partial
complementary sequences at 50 and 30
regions. These regions are critical for viral
replication, transcription, and translation,
presumablyby formingbasepairs, astruc-
ture also known as the panhandle. Be-
cause the presumed panhandle regions
of the viral genomes contain blunt-ended
50 tri-p structure, these might serve as
strong agonists for RIG-I. Indeed, Schlee
et al. (2009) synthesized a Rabies viral
panhandle (without a pan) and demon-
strated that it can activate RIG-I.
RIG-I is composed of three main
domains. The ATPase-RNA helicase
domain of RIG-I is the largest portion of
RIG-I and is implicated for conformational
change upon activation. The C-terminal
region is responsible for RNA recognition
(Cui et al., 2008; Takahasi et al., 2008).
The N-terminal domain containing
tandem repeat of caspase activation and
recruitment domain (CARD) is responsible
for relaying the signal to downstream
effectors (Yoneyama and Fujita, 2009). It
has been proposed that in a repressed
state, CARD is masked by the action of
the C-terminal domain; however, upon
RNA binding, conformational change is
induced, thereby exposing CARD (Taka-
hasi et al., 2008).
Schmidt et al. (2009) demonstrated that
both 50 tri-p and short dsRNA moiety,
respectively, form a complex with RIG-I.
Furthermore, a biologically active RNA
molecule with both of these structures
induces a RIG-I dimer. Taken together,
these results suggest a new model
(Figure 1) in which 50 tri-p and double-
stranded structures present in one RNA
molecule bridge two RIG-I molecules to
facilitate RIG-I dimer (oligomer) formation,
which has been observed in virus-in-
fected cells (Saito et al., 2007). However,
there are several issues to be resolved
before finalizing this model, particularly,
the mechanism of recognition of the two
nonself signatures by domains of RIG-I
should be elucidated.
Schlee et al. (2009) and Schmidt et al.
(2009) uncovered that 50 tri-p and
panhandle structures of viral RNA are
crucial for RIG-I activation to initiate an
antiviral response program. The dual
detection facilitates highly specific recog-
nition and avoids unnecessary activation
of the IFN system, which is sometimes
toxic to normal cellular function.
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The interleukin-1 (IL-1)-like cytokine IL-33 is widely assumed to undergo proteolyticmaturation by caspase-1.
In this issue of Immunity, Lu¨thi et al. (2009) show that IL-33 is not a caspase-1 substrate. IL-33 is inactivated
by caspase-3 and -7 to prevent an inappropriate immune response during apoptosis, but not in necrosis.
Interleukin-33 (IL-33) was initially des-
cribed as ‘‘nuclear factor from high endo-
thelial venules’’ (NF-HEV) because it re-
sided in the nucleus of high endothelial
cells (Baekkevold et al., 2003). These cells
form ‘‘high endothelial venules’’ (HEVs) in
secondary lymphoid tissue and serve as
entry sites for extravasating lymphocytes.
More recently, nuclear IL-33 was also
detected in epithelial and non-HEV endo-
thelial cells (Moussion et al., 2008). Its
nuclear localization in these cells was ex-
plained by the presence of an amino-
terminal homeodomain-like DNA-binding
motif (Baekkevold et al., 2003). AlthoughImmunity 31, July 17, 2009 ª2009 Elsevier Inc. 5
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PreviewsFigure 1. IL-33 Responses in Necrosis and Apoptosis
IL-33 is constitutively expressed in the nucleus of endothelial and epithelial cells, where it may be involved
in regulating transcription through its amino-terminal homeodomain-like DNA-binding motif. Tissue
damage during trauma or infection triggers secretion of full-length IL-33 from necrotic cells. Extracellular
IL-33 engages the IL-1 receptor family member ST2. In association with an IL-1R accessory protein (IL-
1RAcP), this leads to NF-kB-mediated secretion of proinflammatory and Th2 cell-associated cytokines
frommast cells and other immune cells to alert the immune system and to promote the initiation of healing
responses. During apoptosis, the executioner caspase-3 and -7 inactivate IL-33 by cleaving the carboxy-
terminal IL-1-like b-trefoil domain. Although processed IL-33 is largely retained inside apoptotic bodies,
caspase-mediated processing prevents accidentally released IL-33 from stimulating the ST2 receptor.the exact function of endogenous IL-33 in
the nucleus has not been established,
overexpression studies suggested a role
in transcriptional repression (Carriere
et al., 2007).
In 2005, mining of genomic and ex-
pressed sequence tag (EST) databases
led to the rediscovery of IL-33 as an
IL-1-like protein (Schmitz et al., 2005). It
shares with other IL-1 family members
the presence of a b-trefoil fold in its
carboxy-terminus. Moreover, IL-33 was
identified as an extracellular ligand for
the orphan IL-1 receptor (IL-1R) family
member ST2 (Schmitz et al., 2005), which
signals in conjunction with IL-1R acces-
sory protein (IL-1RAcP) (Ali et al., 2007;
Chackerian et al., 2007). IL-33 binding of
the ST2 receptor on mast cells and T
helper 2 (Th2) lymphocytes triggers se-
cretion of proinflammatory and the Th2
cell-associated cytokines IL-4, IL-5, and
IL-13 (Ali et al., 2007; Chackerian et al.,
2007; Schmitz et al., 2005). These findings
paved the way to unraveling the role of
IL-33 in inflammatory, infectious, and
autoimmune diseases, but also raised
the question how the protein migrates
from its nuclear localization in endothelial
and epithelial cells to the extracellular ST26 Immunity 31, July 17, 2009 ª2009 Elsevierreceptor on mast cells and other immune
cells.
A widely held explanation for the
release of IL-33 is based on the unique
secretory mechanism of two other cyto-
kines of the IL-1 family, IL-1b and IL-18.
Whereas most cytokines traffic through
the Golgi complex prior to exocytosis,
IL-1b and IL-18 are produced as biologi-
cally inactive precursors that reside in the
cytosolic compartment. In response to an
inflammatory insult, they are proteolyti-
cally matured by the cysteine protease
caspase-1 (Lamkanfi and Dixit, 2009).
Because of its homology to IL-1b and
IL-18 and the absence of an apparent
secretory signal peptide, IL-33 was widely
assumed to be synthesized as a 31-kDa
precursor from which the biologically
active cytokine was liberated by cas-
pase-1. In this issue of Immunity, Lu¨thi
et al. (2009) now showed this model to be
incorrect. They show that concentrations
of recombinant caspase-1 that achieve
robust maturation of IL-1b fail to process
human and mouse IL-33. In addition, full-
length IL-33 displays potent biological
activity, further arguing that unlike IL-1b
and IL-18 precursors, IL-33 does not
require caspase-1 processing. AnotherInc.recently published report independently
arrived at these conclusions (Talabot-
Ayer et al., 2009). A third concomitant
report observed caspase-1-dependent
processing of IL-33 in rabbit reticulocyte
lysates; however, this led to inactivation
of IL-33 rather than its activation (Cayrol
and Girard, 2009). Importantly, the identi-
fied cleavage site (DGVD178 in human
IL-33 and DGVD175 in mouse IL-33)
does not resemble preferred caspase-1
cleavage sites but closely matches pro-
cessing sites of the apoptotic caspase-3
and -7. This suggests that recombinant
caspase-1 may have activated endoge-
nous caspase-3 or -7 in the reticulocyte
lysates. Indeed, recombinant caspases-3
and -7 readily processed human and
mouse IL-33 after Asp178 and Asp175,
respectively (Cayrol and Girard, 2009; Lu¨-
thi et al., 2009). Further, unlike IL-33D178A
mutant, wild-type IL-33 was processed in
cells undergoing apoptosis in response
to a variety of DNA-damaging agents and
when treated with anti-Fas, TRAIL, or
TNF-aplus cycloheximide (Cayrol andGir-
ard, 2009; Lu¨thi et al., 2009). Finally, IL-33
was cleaved in apoptotic murine embry-
onic fibroblast (MEF) cells lacking cas-
pase-1 or -7, but not those deficient for
caspase-3 (Lu¨thi et al., 2009).
Surprisingly, although caspase-7-
cleaved IL-33 failed to activate the ST2
receptor, its binding to the receptor was
comparable to that of full-length IL-33 (Lu¨-
thi et al., 2009). However, this experiment
has tobe interpretedwith cautionbecause
the caspase-7-incubation setup was not
devoid of unprocessed IL-33. It would
be interesting to assess receptor binding
of the separately generated N- and
C-terminal (IL-331–178 and IL-33179–270)
fragments, although it is clear that they
are incapable of activating ST2 receptor
signaling (Cayrol and Girard, 2009; Lu¨thi
et al., 2009). Strong ST2 binding of one
of the fragments in the absence of re-
ceptor activation may suggest a poten-
tially novel approach to interfere with ST2
signaling. An increased vulnerability to
degradation by serumproteaseswas sug-
gested as a potential explanation for the
reduced biological activity of caspase-7-
cleaved IL-33 in the absence of a loss of
receptor binding (Lu¨thi et al., 2009).
Because Asp178 is located within the IL-
1-like b-trefoil domain of IL-33 (Schmitz
et al., 2005), processing at this position
may also destabilize the b-trefoil structure
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with the ST2 receptor.
But when is IL-33 secreted? Unlike
IL-1b, which is readily secreted by
macrophages and dendritic cells after
stimulation with LPS and PMA, IL-33 re-
mained intracellular (Lu¨thi et al., 2009). In
apoptotic macrophages, caspase-medi-
ated processing ensured inactivation of
IL-33, but the processing fragments
were nevertheless kept cell associated.
In contrast, most IL-33 was released
from macrophages induced to undergo
necrotic cell death (Lu¨thi et al., 2009). As
expected, IL-33 was not processed in
necrotic endothelial cells (Cayrol and Gir-
ard, 2009) because caspases are not acti-
vated during this cell death process.
Together, these findings suggest that
IL-33 is specifically released during
necrotic cell death, which is thought to
be associated with tissue damage during
trauma or infection. Under these condi-
tions, extracellular IL-33 may engage the
ST2 receptor on mast cells and other
immune cells in order to alert the immune
system of tissue damage and infection
and to promote the initiation of healing
responses (Figure 1). In support of this
hypothesis, IL-33 is highly expressed inIntegr-ating IL-1a
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currently unknown. In this issue of
induced inflammation and identify t
To combat invading viruses and survive
infection, eukaryotic hosts deploy an
arsenal of defensive measures. The first
of these is the innate immune system.
Innate immunity controls virus infection
and elicits the T and B cell responses of
adaptive immunity, which are required to
eliminate virus-infected cells. Several
classes of germline-encoded patternendothelial cells of most organs and in
the epidermal and gastrointestinal epithe-
lium (Moussion et al., 2008). These tissues
may become exposed to pathogens,
allergens, and other environmental agents
that can trigger tissue damage. In this
respect, IL-33 appears highly reminiscent
of IL-1a and HMGB1, two dual-function
proteins that play important roles as
both intracellular nuclear proteins and
extracellular cytokines. Moreover, all
three proteins lack classical secretion
signals and display cytokine activity inde-
pendently of processing. In addition, all
three are released by necrotic cells,
but kept intracellular during apoptosis.
Because of these features, HMGB1 and
IL-1a have been referred to as ‘‘endoge-
nous danger signals’’ or ‘‘alarmins.’’ The
work by Lu¨thi et al. (2009) now also
bestows IL-33 with this title.
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